LAUSR

osli S, Kostylina G et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122–8. 7 Mendes AM, Costa ACC, Luz S et al. Omalizumab – one year experience in the treatment of severe atopic dermatitis. J Allergy Clin Immunol 2012; 129:AB38. 8 Hotze M, Baurecht H, Rodr ıguez E et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014; 69:132–5. 9 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27:485–517. 10 Di Cesare A, Di Meglio P, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 2008; 128:2569–71. 11 Khattri S, Brunner PM, Garcet S et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 2017; 26:28–35. 12 Saeki H, Kabashima K, Tokura Y et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 2017; 177:419–27. 13 Noda S, Su arez-Fari~ nas M, Ungar B et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased Th17 polarization. J Allergy Clin Immunol 2015; 136:1254–64. 14 Schram ME, Spuls PI, Leeflang MMG et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67:99–106. 15 Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839–46. 16 APRICOT. Anakinra trial. Available at: http://apricot-trial.com/ab out-the-trial/2016 (last accessed 21 July 2017).